JAMA. Published online February 5, 2021. doi:10.1001/jama.2021.1225
Monoclonal antibodies, designed to mimic the body’s natural immune response, are available as treatment for COVID-19 for patients at high risk of progression to severe disease.
There are several approved treatments for coronavirus disease 2019 (COVID-19) in hospitalized patients but few for patients who are not sick enough to be hospitalized. Monoclonal antibodies are a new treatment for outpatients with COVID-19 who are at risk of progression to severe disease.
Read more here : https://jamanetwork.com/journals/jama/fullarticle/2776307?utm_source=silverchair&utm_campaign=jama_network&utm_content=covid_weekly_highlights&utm_medium=email
Comments